Skip to main content
Equibles
MBX logo

MBX · MBX Biosciences, Inc. · Financials

Track MBX — free

Use MBX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MBX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$59.02 -1.92 (-3.15%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$2.84B
Shares
48.16M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Net Income
-$87M -40.5%
FY2025 Net Income FY2023–FY2025
Diluted EPS
-$2.38 +59.1%
FY2025 Diluted EPS FY2023–FY2025
Operating Cash Flow
-$79.95M -46.2%
FY2025 Operating Cash Flow FY2023–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2025 FY2024 FY2023
$88.49M $79.16M $57.42M $28.53M
$29.43M $18.9M $10.78M $6.78M
$117.92M $98.06M $68.19M $35.31M
-$117.92M -$98.06M -$68.19M -$35.31M
— -$87M -$61.9M —
— $0 $0 $0
-$104.32M -$87M -$61.92M -$32.56M
-$104.29M -$86.97M -$61.92M -$32.56M
-$105.53M -$86.74M -$61.93M -$32.51M
USD/shares -$2.37 -$2.38 -$5.82 -$31.96
USD/shares -$2.37 -$2.38 -$5.82 -$31.96
shares — 36.51M 10.64M 1.02M
shares — 36.51M 10.64M 1.02M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 8.50×
EV/EBIT
—
Peer median 16.61×
P/E (TTM)
—
Peer median 17.59×

Peer medians compare against the 229 similar-size Biotechnology companies (of 536 listed).

Key facts CIK 1776111 CUSIP 55287L101 13F (30d) 101 filings 101 filers Visit website Investor relations